Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Gastric Cancer | Correction

Correction to: Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression

Authors: Dong-liang Chen, Huai-qiang Ju, Yun-xin Lu, Le-zong Chen, Zhao-lei Zeng, Dong-sheng Zhang, Hui-yan Luo, Feng Wang, Miao-zhen Qiu, De-shen Wang, Da-zhi Xu, Zhi-wei Zhou, Helene Pelicano, Peng Huang, Dan Xie, Feng-hua Wang, Yu-hong Li, Rui-hua Xu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Excerpt

Correction to: J Exp Clin Cancer Res 35, 142 (2016) …
Literature
1.
Chen DL, Ju HQ, Lu YX, Chen LZ, Zeng ZL, Zhang DS, et al. Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. J Exp Clin Cancer Res. 2016;35(1):142.CrossRef
Metadata
Title
Correction to: Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression
Authors
Dong-liang Chen
Huai-qiang Ju
Yun-xin Lu
Le-zong Chen
Zhao-lei Zeng
Dong-sheng Zhang
Hui-yan Luo
Feng Wang
Miao-zhen Qiu
De-shen Wang
Da-zhi Xu
Zhi-wei Zhou
Helene Pelicano
Peng Huang
Dan Xie
Feng-hua Wang
Yu-hong Li
Rui-hua Xu
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-02002-9

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue

Correction

Correction to: Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ

Research

CircFAM73A promotes the cancer stem cell-like properties of gastric cancer through the miR-490-3p/HMGA2 positive feedback loop and HNRNPK-mediated β-catenin stabilization

Research

Identification of novel COX-2 / CYP19A1 axis involved in the mesothelioma pathogenesis opens new therapeutic opportunities

Review

An immunotherapeutic approach to decipher the role of long non-coding RNAs in cancer progression, resistance and epigenetic regulation of immune cells

Research

Deciphering the temporal heterogeneity of cancer-associated fibroblast subpopulations in breast cancer

Review

Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits